In vivo involvement of the cholinergic and dopaminergic systems in the pathophysiology of apathy. ADACHOL.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518721-15-00

Enrollment

Registered

2024-11-14

Start date

2021-04-13

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apathy

Brief summary

[18F]-FEOBV and [18F]-FDOPA binding intensities

Detailed description

Clinical severity of apathy, Functional connectivity parameters measured with MRI, Diffusion tensor imaging parameters, such as the fractional anisotropy and mean diffusivity, measured with structural MRI, Cerebral blood flow

Interventions

DRUGFluoroethoxybenzovesamicol F-18

DRUGDopacis 90 MBq/mL

DRUGsolution injectable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
[18F]-FEOBV and [18F]-FDOPA binding intensities	—

Secondary

Measure	Time frame
Clinical severity of apathy, Functional connectivity parameters measured with MRI, Diffusion tensor imaging parameters, such as the fractional anisotropy and mean diffusivity, measured with structural MRI, Cerebral blood flow	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026